These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1981586)

  • 21. The effect of immunization with digoxin-specific antibodies on digoxin disposition in the mouse.
    Griffiths NM; Hewick DS; Stevenson IH
    Biochem Pharmacol; 1984 Oct; 33(19):3041-6. PubMed ID: 6487355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the neutralizing activity of digoxin-specific Fab toward ouabain-like steroids.
    Pullen MA; Brooks DP; Edwards RM
    J Pharmacol Exp Ther; 2004 Jul; 310(1):319-25. PubMed ID: 14982968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrasting rates of reversal of digoxin toxicity by digoxin-specific IgG and Fab fragments.
    Lloyd BL; Smith TW
    Circulation; 1978 Aug; 58(2):280-3. PubMed ID: 668076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma.
    Tayab ZR; Balthasar JP
    J Immunoassay Immunochem; 2004; 25(4):335-44. PubMed ID: 15552588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fab antibody fragments: some applications in clinical toxicology.
    Flanagan RJ; Jones AL
    Drug Saf; 2004; 27(14):1115-33. PubMed ID: 15554746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analytical control procedures of immunoreactivity for IgG and Fab fragments specific to haptens.
    Cano NJ; Sabouraud AE; Urtizberea M; Carcagne J; Grandgeorge M; Scherrmann JM
    Pharm Res; 1992 May; 9(5):643-7. PubMed ID: 1608896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Digoxin-specific Fab fragments impair renal function in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1992 Oct; 44(10):867-9. PubMed ID: 1360517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related differences in digoxin toxicity and its treatment.
    Wells TG; Young RA; Kearns GL
    Drug Saf; 1992; 7(2):135-51. PubMed ID: 1605899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.
    Bazin-Redureau M; Pepin S; Hong G; Debray M; Scherrmann JM
    Toxicol Appl Pharmacol; 1998 Jun; 150(2):295-300. PubMed ID: 9653060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments.
    Lechat P; Mudgett-Hunter M; Margolies MN; Haber E; Smith TW
    J Pharmacol Exp Ther; 1984 Apr; 229(1):210-3. PubMed ID: 6707937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs.
    Butler VP; Schmidt DH; Smith TW; Haber E; Raynor BD; Demartini P
    J Clin Invest; 1977 Feb; 59(2):345-59. PubMed ID: 299860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time- and dose-dependent digoxin redistribution by digoxin-specific antigen binding fragments in a rat model.
    Renard C; Weinling E; Pau B; Scherrmann JM
    Toxicology; 1999 Sep; 137(2):117-27. PubMed ID: 10521148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic effects of the Fab fragment of digoxin antibody (digibind) in corticotropin (ACTH)-induced hypertension.
    Li M; Wen C; Whitworth JA
    Am J Hypertens; 1997 Mar; 10(3):332-6. PubMed ID: 9056691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind.
    Ward SB; Sjostrom L; Ujhelyi MR
    Ther Drug Monit; 2000 Oct; 22(5):599-607. PubMed ID: 11034267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of digoxin in sheep: limitations of the use of biological half-life for interspecies extrapolation.
    Dix LP; Bai SA; Rogers RA; Anderson DL; Riviere JE
    Am J Vet Res; 1985 Feb; 46(2):470-2. PubMed ID: 3994115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: timing is important for maximizing clearance.
    Zdunek M; Mitra A; Mokrzycki MH
    Am J Kidney Dis; 2000 Jul; 36(1):177-83. PubMed ID: 10873888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab.
    Shatz W; Hass PE; Mathieu M; Kim HS; Leach K; Zhou M; Crawford Y; Shen A; Wang K; Chang DP; Maia M; Crowell SR; Dickmann L; Scheer JM; Kelley RF
    Mol Pharm; 2016 Sep; 13(9):2996-3003. PubMed ID: 27244474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs.
    Owens SM; Mayersohn M
    Drug Metab Dispos; 1986; 14(1):52-8. PubMed ID: 2868866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of digoxin in newborn and adult sheep.
    Berman W; Musselman J; Shortencarrier R
    J Pharmacokinet Biopharm; 1982 Apr; 10(2):173-86. PubMed ID: 7120047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of digoxin antibodies on digoxin disposition and effect: studies in guinea-pigs and HeLa cells.
    Griffiths NM; Hewick DS; Lamb JF; Stevenson IH
    Br J Pharmacol; 1985 Jan; 84(1):157-63. PubMed ID: 3978308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.